Revelation Partners

Revelation Partners, LLC, established in 2012 and based in Sausalito, California, is a private equity firm specializing in secondary investments within the healthcare sector. It focuses on medical devices, biopharmaceuticals, healthcare IT, and services, targeting late-stage companies with proven business models or novel technologies. The firm invests between $5 million and $30 million, with the capacity to participate in larger deals alongside limited partners. Revelation Partners typically seeks majority stakes and also provides follow-on investments.

Garrett Brown

Senior Associate

Doug Fisher

Partner

Keegan Hasson

Senior Associate

Fred Lee

Partner

Fred Lee

Partner

Courtney Munley

Associate

Andrew Olson

Partner, CFO and COO

Andrew Olson

Partner, CFO and COO

Rob Rein

Vice President

Liz Staley

Partner and CCO

50 past transactions

Arbor Biotechnologies

Series C in 2025
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

VitalConnect

Venture Round in 2025
VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

SPR Therapeutics

Series D in 2024
SPR Therapeutics is a medical device company that develops and commercializes peripheral nerve stimulation (PNS) therapies for pain management. It focuses on non-narcotic, reversible treatments for acute and chronic pain, including post-surgical pain and neuropathic pain, as well as phantom limb and musculoskeletal pain. The SMARTPATCH PNS system provides short-term, minimally invasive nerve stimulation to relieve pain, and the portfolio includes the Micropulse implantable PNS system for longer-term therapy and Smartpatch MicroLead, a coiled-wire lead designed to promote rapid tissue ingrowth. Founded in 2009 and headquartered in Cleveland, Ohio, with additional locations in the Research Triangle area and Minneapolis, SPR Therapeutics aims to offer safe, effective, and affordable pain relief as an alternative to opioids and invasive procedures.

Nouscom

Series C in 2023
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

VitalConnect

Series F in 2023
VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Carrum Health

Series B in 2023
Carrum Health is an online healthcare platform focused on simplifying the healthcare payment model for employers and their employees. By establishing direct connections between progressive self-insured employers and top-quality regional healthcare providers, Carrum Health offers a comprehensive bundled payment solution that enhances the value of health benefits. The platform aims to reduce healthcare costs for patients, often leading to low or zero out-of-pocket expenses. Through this innovative approach, Carrum Health seeks to streamline the delivery and financing of healthcare, making it more accessible and affordable for both employers and their workforce.

Vedanta Biosciences

Series E in 2023
Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Bristol Hospice

Venture Round in 2023
Bristol Hospice, established in 2006, specializes in delivering hospice and palliative care services to patients, families, and communities. The organization focuses on promoting quality and comprehensive care tailored to the needs of those it serves. Its offerings include nursing, physician services, home health aides, counseling, spiritual support, therapy, dietary assistance, and bereavement services. Additionally, Bristol Hospice provides durable medical equipment and supplies, ensuring that customers receive support for their physical, psychosocial, and spiritual needs. Through its strategic planning, the company aims to enhance the quality of life for individuals facing serious illnesses.

Carrick Therapeutics

Series C in 2022
Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.

Syapse

Venture Round in 2022
Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Iris Telehealth

Series B in 2022
Iris Telehealth provides telepsychiatry services to community mental health centers, community health centers, hospitals and health systems across the United States. It connects facilities with trained mental health professionals through private videoconference, enabling patients to receive appropriate care without traveling. The service supports clinicians in delivering timely psychiatric care, aims to improve patient outcomes, and offers scalable access to mental health services.

IntelyCare

Series C in 2022
IntelyCare is a digital healthcare workforce platform that combines a gig-model mobile app with data-driven analytics to fill nursing shifts at post-acute facilities, long-term care communities, home care agencies, and rehab hospitals. The platform enables nursing professionals to view, browse, and select shifts while automating scheduling, forecasting staffing needs, and verifying licenses, helping facilities optimize staffing, reduce burnout, and improve productivity.

Gravie

Series E in 2022
Founded in 2013, Gravie operates a health insurance platform that enables individuals and businesses to compare and select insurance plans both on-exchange and off-exchange. It offers custom benefits planning, financial analysis, year-round support, and a mobile application for convenient access.

Gravie

Series E in 2022
Founded in 2013, Gravie operates a health insurance platform that enables individuals and businesses to compare and select insurance plans both on-exchange and off-exchange. It offers custom benefits planning, financial analysis, year-round support, and a mobile application for convenient access.

Omada Health

Series E in 2022
Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Click Therapeutics

Series B in 2021
Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

SPR Therapeutics

Series D in 2021
SPR Therapeutics is a medical device company that develops and commercializes peripheral nerve stimulation (PNS) therapies for pain management. It focuses on non-narcotic, reversible treatments for acute and chronic pain, including post-surgical pain and neuropathic pain, as well as phantom limb and musculoskeletal pain. The SMARTPATCH PNS system provides short-term, minimally invasive nerve stimulation to relieve pain, and the portfolio includes the Micropulse implantable PNS system for longer-term therapy and Smartpatch MicroLead, a coiled-wire lead designed to promote rapid tissue ingrowth. Founded in 2009 and headquartered in Cleveland, Ohio, with additional locations in the Research Triangle area and Minneapolis, SPR Therapeutics aims to offer safe, effective, and affordable pain relief as an alternative to opioids and invasive procedures.

Honor

Series E in 2021
Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.

US Fertility

Private Equity Round in 2021
US Fertility is a leading fertility practice management company that supports top-tier fertility programs across the United States. It offers advanced business and digital solutions, including technology platforms for clinical and operational management, enabling partner practices to enhance patient care and improve financial performance.

Genome Medical

Series C in 2021
Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Singular Genomics

Convertible Note in 2021
Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Gravie

Series D in 2021
Founded in 2013, Gravie operates a health insurance platform that enables individuals and businesses to compare and select insurance plans both on-exchange and off-exchange. It offers custom benefits planning, financial analysis, year-round support, and a mobile application for convenient access.

Gravie

Series D in 2021
Founded in 2013, Gravie operates a health insurance platform that enables individuals and businesses to compare and select insurance plans both on-exchange and off-exchange. It offers custom benefits planning, financial analysis, year-round support, and a mobile application for convenient access.

Nuvolo

Series C in 2021
Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

SetPoint Medical Corporation

Venture Round in 2021
SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

SomaLogic

Series A in 2020
Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Included Health

Series E in 2020
Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

NeuroPace

Private Equity Round in 2020
NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

MISSION Therapeutics

Venture Round in 2020
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Evidation Health

Series D in 2020
Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Genome Medical

Series B in 2020
Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Arterys

Series C in 2020
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

Syapse

Series F in 2020
Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

IntelyCare

Series B in 2020
IntelyCare is a digital healthcare workforce platform that combines a gig-model mobile app with data-driven analytics to fill nursing shifts at post-acute facilities, long-term care communities, home care agencies, and rehab hospitals. The platform enables nursing professionals to view, browse, and select shifts while automating scheduling, forecasting staffing needs, and verifying licenses, helping facilities optimize staffing, reduce burnout, and improve productivity.

Arcadia Solutions

Venture Round in 2020
Arcadia Solutions, LLC is a healthcare technology company based in Burlington, Massachusetts, specializing in electronic health record (EHR) data aggregation and analytics. Founded in 2002, Arcadia provides a suite of services and proprietary software aimed at large healthcare providers, payors, accountable care organizations, and health information exchanges. The company offers various IT services, including EHR implementation and optimization, performance management, and information security solutions. Additionally, Arcadia develops customizable tools for planning and maintaining health IT infrastructures, which include monitoring services to evaluate key performance indicators and manage technology lifecycle needs. By integrating diverse healthcare data into a unified platform, Arcadia enables organizations to derive actionable insights that enhance care, support research, and drive strategic growth while ensuring financial success.

Singular Genomics

Venture Round in 2019
Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Providence Medical Technology

Venture Round in 2018
Providence Medical Technology is a medical device company specializing in innovative solutions for cervical spinal conditions. It offers the DTRAX platform, including instruments and implants designed to treat cervical degenerative disc disease via indirect decompression and fusion.

Headspace

Series B in 2017
Headspace is a mental health technology company that provides a digital platform for mindfulness and emotional well‑being. Its mobile app offers guided meditations, sleep aids, and mindfulness programs for work, relationships, and health. The service expands beyond meditation to include clinical content, coaching, therapy, psychiatry, and AI‑driven care navigation, allowing individuals, employees, and health plan members to access personalized support. Headspace partners with organizations to deliver corporate wellness programs that improve employee productivity and well‑being.

Vertos Medical

Venture Round in 2017
Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis, a common spinal condition. Founded in 2005 and headquartered in Aliso Viejo, California, the company develops and markets its mild device, which provides an outpatient treatment option that is fluoroscopically guided and does not require implants. This device encompasses a range of instruments including tissue sculptors, surgical clamps, and bone sculpters, allowing physicians to effectively relieve pressure on the spinal nerves and restore mobility with local anesthesia. Vertos Medical’s innovative approach offers patients a less invasive option compared to traditional lumbar decompression surgeries, making significant advancements in spinal healthcare.

Prolacta Bioscience

Venture Round in 2016
Founded in 1999, Prolacta Bioscience specializes in developing and producing standardized human milk-based nutritional products for premature and critically ill infants in neonatal intensive care units (NICUs). Its portfolio includes human milk fortifiers, caloric fortifiers, standardized human milk, premature infant formulas, and solutions for early/trophic feeds. The company operates a pharmaceutical-grade processing plant, ensuring the quality and safety of its products.

ClearCorrect

Private Equity Round in 2016
ClearCorrect, LLC is a manufacturer of clear aligners designed to straighten teeth without the use of metal braces. Founded in 2006 and based in Round Rock, Texas, the company produces custom, removable aligners tailored to each patient's needs based on their dentist's or orthodontist's prescription. These aligners gradually shift teeth into the desired position, providing a comfortable and discreet alternative to traditional orthodontic methods. ClearCorrect aims to offer an affordable and effective solution for teeth alignment, benefiting both patients and dental professionals. As of September 2017, ClearCorrect operates as a subsidiary of Straumann Holding AG.

Cerapedics

Series D in 2016
Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Akili Interactive

Series B in 2016
Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Bluesight

Series B in 2015
Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.